DBV Technologies Initiates $150 Million At-The-Market Offering

DBV Technologies, a biopharmaceutical company, has filed a shelf registration with the U.S. SEC to sell up to $150 million in American Depositary Shares (ADS) through its At-The-Market (ATM) program. This program was refreshed under an agreement with Citizens JMP Securities, allowing for ADS sales representing five ordinary shares each, pending French regulatory limits and not subject to AMF approval.

The funds are earmarked for manufacturing, product development, and launching Viaskin Peanut for young children, dependent on regulatory approval. The filing is automatically effective, ensuring legal compliance across jurisdictions. The offering's documents are freely available on the SEC website, ensuring transparency.